| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBS-K028 | Human | Human TROP-2-coupled Magnetic Beads |
|
||
| TR2-C52H4 | Canine | Canine TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-R52H3 | Rhesus macaque / Cynomolgus | Rhesus macaque / Cynomolgus TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
| TR2-M52H6 | Mouse | Mouse TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-H5253 | Human | Human TROP-2 / TACSTD2 Protein, Fc Tag |  |
|
|
| TR2-H82E5 | Human | Biotinylated Human TROP-2 / TACSTD2 Protein, His,Avitag™ |  |
|
|
| TR2-H5223 | Human | Human TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) is more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | TROP-2-SN-38; GS-0132; IMMU0132; IMMU-132 | Approved | Immunomedics Inc | Trodelvy | Singapore | Triple Negative Breast Neoplasms | Everest Medicines Ltd | 2020-04-22 | Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Metastatic breast cancer; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SKB-264 | SKB-264 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BAT-8003 | BAT-8003 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
| FDA018 Antibody Drug Conjugate | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours | Details | |
| DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma | Details |
| 重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
| Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z
